Visanji NP - Search Results

1

Visanji NP, Marras C, Liu LW, Hazrati LN, Lang AE. Visanji NP, et al. Mov Disord. 2014 Aug;29(9):1225-6. doi: 10.1002/mds.25941. Epub 2014 Jun 12. Mov Disord. 2014. PMID: 24925804 No abstract available.

2

Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Gomez-Ramirez J, Johnston TH, Visanji NP, Fox SH, Brotchie JM. Gomez-Ramirez J, et al. Among authors: visanji np. Mov Disord. 2006 Jun;21(6):839-46. doi: 10.1002/mds.20828. Mov Disord. 2006. PMID: 16532454

3

Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Visanji NP, Gomez-Ramirez J, Johnston TH, Pires D, Voon V, Brotchie JM, Fox SH. Visanji NP, et al. Mov Disord. 2006 Nov;21(11):1879-91. doi: 10.1002/mds.21073. Mov Disord. 2006. PMID: 16960862

4

The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Visanji NP, de Bie RM, Johnston TH, McCreary AC, Brotchie JM, Fox SH. Visanji NP, et al. Mov Disord. 2008 Oct 15;23(13):1922-5. doi: 10.1002/mds.22086. Mov Disord. 2008. PMID: 18759357

5

Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations.

Huot P, Johnston TH, Darr T, Hazrati LN, Visanji NP, Pires D, Brotchie JM, Fox SH. Huot P, et al. Among authors: visanji np. Mov Disord. 2010 Jul 30;25(10):1399-408. doi: 10.1002/mds.23083. Mov Disord. 2010. PMID: 20629135

6

A proteomic analysis of pediatric seizure cases associated with astrocytic inclusions.

Visanji NP, Wong JC, Wang SX, Cappel B, Kleinschmidt-Demasters BK, Handler MH, Ochi A, Otsubo H, Rutka JT, Go C, Weiss S, Vinters HV, Hawkins CE, Desouza LV, Siu KW, Hazrati LN. Visanji NP, et al. Epilepsia. 2012 Mar;53(3):e50-4. doi: 10.1111/j.1528-1167.2011.03369.x. Epub 2012 Jan 5. Epilepsia. 2012. PMID: 22220588 Free article.

7

Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease.

Huot P, Johnston TH, Visanji NP, Darr T, Pires D, Hazrati LN, Brotchie JM, Fox SH. Huot P, et al. Among authors: visanji np. Mov Disord. 2012 May;27(6):735-42. doi: 10.1002/mds.24964. Epub 2012 Mar 14. Mov Disord. 2012. PMID: 22419526

8

Iron deficiency in parkinsonism: region-specific iron dysregulation in Parkinson's disease and multiple system atrophy.

Visanji NP, Collingwood JF, Finnegan ME, Tandon A, House E, Hazrati LN. Visanji NP, et al. J Parkinsons Dis. 2013;3(4):523-37. doi: 10.3233/JPD-130197. J Parkinsons Dis. 2013. PMID: 24113558

9

The prion hypothesis in Parkinson's disease: Braak to the future.

Visanji NP, Brooks PL, Hazrati LN, Lang AE. Visanji NP, et al. Acta Neuropathol Commun. 2013 May 8;1:2. doi: 10.1186/2051-5960-1-2. Acta Neuropathol Commun. 2013. PMID: 24252164 Free PMC article. Review.

10

Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker.

Visanji NP, Marras C, Hazrati LN, Liu LW, Lang AE. Visanji NP, et al. Mov Disord. 2014 Apr;29(4):444-50. doi: 10.1002/mds.25789. Epub 2013 Dec 26. Mov Disord. 2014. PMID: 24375496 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

81 results

Search Page

Filters